W dniach od 2 kwietnia do 5 kwietnia 2024 r. prowadzone będą prace związane z wdrożeniem nowej wersji systemu Repozytorium UJ. Nie będzie możliwe wprowadzanie nowych informacji do repozytorium. Za utrudnienia przepraszamy.
High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta
pl
dc.type
JournalArticle
pl
dc.description.physical
[1-13]
pl
dc.abstract.en
Increased levels of a soluble form of endoglin (sEng) circulating in plasma have been detected in various pathological conditions related to cardiovascular system. High concentration of sEng was also proposed to contribute to the development of endothelial dysfunction, but there is no direct evidence to support this hypothesis. Therefore, in the present work we analyzed whether high sEng levels induce endothelial dysfunction in aorta by using transgenic mice with high expression of human sEng. Transgenic mice with high expression of human sEng on CBAxC57Bl/6J background (Sol-Eng+) and age-matched transgenic littermates that do not develop high levels of human soluble endoglin (control animals in this study) on chow diet were used. As expected, male and female Sol-Eng+ transgenic mice showed higher levels of plasma concentrations of human sEng as well as increased blood arterial pressure, as compared to control animals. Functional analysis either in vivo or ex vivo in isolated aorta demonstrated that the endothelium-dependent vascular function was similar in Sol-Eng+ and control mice. In addition, Western blot analysis showed no differences between Sol-Eng+ and control mice in the protein expression levels of endoglin, endothelial NO-synthase (eNOS) and pro-inflammatory ICAM-1 and VCAM-1 from aorta. Our results demonstrate that high levels of soluble endoglin alone do not induce endothelial dysfunction in Sol-Eng+ mice. However, these data do not rule out the possibility that soluble endoglin might contribute to alteration of endothelial function in combination with other risk factors related to cardiovascular disorders.
pl
dc.description.volume
10
pl
dc.description.number
3
pl
dc.description.points
40
pl
dc.identifier.doi
10.1371/journal.pone.0119665
pl
dc.identifier.eissn
1932-6203
pl
dc.title.journal
PLoS ONE
pl
dc.language.container
eng
pl
dc.affiliation
Wydział Lekarski : Zakład Farmakologii Doświadczalnej
pl
dc.affiliation
Pion Rektora : Jagiellońskie Centrum Rozwoju Leków
pl
dc.subtype
Article
pl
dc.identifier.articleid
e0119665
pl
dc.rights.original
CC-BY; otwarte czasopismo; ostateczna wersja wydawcy; w momencie opublikowania; 0;